Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review

Salloum NC, Fava M, Ball S, Papakostas GI.Mol Psychiatry. 2020 Sep;25(9):1967-1974. doi: 10.1038/s41380-020-0646-3. Epub 2020 Jan 27.PMID: 31988433

Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study

Papakostas GI, Fava M, Freeman MP, Shelton RC, Thase ME, Jha MK, Trivedi MH, Dirks B, Liu K, Stankovic S.Int Clin Psychopharmacol. 2020 Nov;35(6):313-321. doi: 10.1097/YIC.0000000000000328.PMID: 32804742 

The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study

Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Fava M, Papakostas GI.Eur Neuropsychopharmacol. 2021 Aug;49:122-132. doi: 10.1016/j.euroneuro.2021.04.024. Epub 2021 Jun 3.PMID: 34090255

REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial

Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, Alimonti A, Bettini E, Mangano RM, Wessel T, de Somer M, Caron J, Vitolo OV, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Folli F, Traversa S, Inturrisi CE, Manfredi PL.Am J Psychiatry. 2021 Dec 22:appiajp202121020197. doi: 10.1176/appi.ajp.2021.21020197. Online ahead of print.PMID: 34933568


Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe

Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu IY, Abbs B, Stankovic S.Lancet Psychiatry. 2022 Jan;9(1):46-58. doi: 10.1016/S2215-0366(21)00386-2. Epub 2021 Nov 30.PMID: 34861170

Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Freeman MP1, Papakostas GI2, Hoeppner B2, Mazzone E2, Judge H2, Cusin C2, Mathew S3, Sanacora G4, Iosifescu D5, DeBattista C6, Trivedi MH7, Fava M2.

 2019 Jan 8;110:166-171. doi: 10.1016/j.jpsychires.2019.01.010.

Sex Differences in Response to Ketamine as A Rapidly Acting Intervention for Treatment Resistant Depression

Marlene P.Freemana | George Papakostasa | Bettina Hoeppnera | Erica Mazzonea | Heidi Judgea | Cristina Cusina | Sanjay Mathew | Gerard Sanacorac | Dan Iosifescud | Charles DeBattistae | Madhukar H.Trivedif | Maurizio Favaa

Received 19 September 2018, Revised 3 January 2019, Accepted 7 January 2019, Available online 8 January 2019.

Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI.

Brain Stimul. 2018 Jan – Feb;11(1):75-84. doi: 10.1016/j.brs.2017.09.010. Epub 2017 Sep 23.